We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the ...

Q1 2025 Management View CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4 ...

Despite a turbulent 2025, Ark Invest CEO Cathie Wood is currently sitting on a big win with her investment in Tempus AI ...

The AstraZeneca deal is also significant for the long-term outlook. Tempus already reported interest from other pharmaceutical giants and may announce additional deals soon. Before you make your ...

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Tempus AI delivered a record quarter, supported by strong revenue growth across its segments and a landmark $200 million agreement with AstraZeneca and Pathos. The company raised its full-year ...